Elevation Oncology reports data from Phase I trial of EO-3021 for solid tumours [Yahoo! Finance]
Elevation Oncology, Inc. - Common stock (ELEV)
Company Research
Source: Yahoo! Finance
The trial focuses on assessing EO-3021 in treating various cancers, including gastric, gastroesophageal junction (GEJ), pancreatic, and oesophageal cancers. As of 10 June 2024, the data cutoff date, 32 patients were treated with EO-3021 across four dose levels in the Phase I trial. Most notably, 26 of them were diagnosed with gastric or GEJ cancer. According to the findings, the treatment was generally well-tolerated, without any reports of Grade 4 or 5 treatment-related adverse events. In addition, less than 10% of subjects discontinued the treatment due to adverse events. No cases of neutropenia or peripheral neuropathy/hypoesthesia were observed among the patients. These conditions are known toxicities associated with monomethyl auristatin E (MMAE), a component often used in cancer therapies, the company noted. Nausea, decreased appetite, fatigue, and diarrhoea were the common treatment-emergent adverse events reported across all grades. Among seven patients with a hig
Show less
Read more
Impact Snapshot
Event Time:
ELEV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELEV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELEV alerts
High impacting Elevation Oncology, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ELEV
News
- Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment ConferencePR Newswire
- Elevation Oncology, Inc. (NASDAQ: ELEV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- Elevation Oncology, Inc. (NASDAQ: ELEV) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.MarketBeat
- Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements [Yahoo! Finance]Yahoo! Finance
- Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business AchievementsPR Newswire
ELEV
Sec Filings
- 9/20/24 - Form 8-K
- 9/18/24 - Form 4
- 8/19/24 - Form 4
- ELEV's page on the SEC website